TigerPaw® System II to launch in the United States this month and in Europe in June 2013
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, announced that it has acquired LAAx Inc., a privately held company that has developed a unique mechanical occlusion device called the TigerPaw® System II ("TigerPaw II"). When implanted, TigerPaw II safely and effectively occludes the left atrial appendage (LAA) and conforms to its shape and thickness, minimizing the risk of tissue damage and accidental bleeding associated with other common closing methods used during open chest procedures. The product has been cleared by regulatory bodies in the United States and European Union and will be commercially available in those regions this month and in June 2013, respectively.